Valarie Clark, NP
Psychiatric/Mental Health · Lake Charles, LANPI 1285288951
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 416 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,125, 3.4 times the $619 reported in 2021. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$975
- Teva Pharmaceuticals USA, Inc.$810
- Alkermes, Inc.$678
- Indivior Inc.$610
- Johnson & Johnson$585
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,15998%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,183 |
| Neurocrine Biosciences, Inc. | 38 | $975 |
| Teva Pharmaceuticals USA, Inc. | 41 | $810 |
| Alkermes, Inc. | 29 | $678 |
| Indivior Inc. | 36 | $610 |
| Johnson & Johnson | 31 | $585 |
| Otsuka America Pharmaceutical, Inc. | 36 | $528 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $498 |
| Axsome Therapeutics, Inc. | 21 | $394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $246 |
| Lundbeck LLC | 12 | $241 |
| Novo Nordisk | 2 | $229 |
| Sunovion Pharmaceuticals Inc. | 10 | $146 |
| Noven Therapeutics, LLC | 7 | $143 |
| Supernus Pharmaceuticals, Inc. | 5 | $122 |
| Gilead | 2 | $115 |
| Bayer | 1 | $114 |
| AstraZeneca | 1 | $114 |
| GSK | 1 | $113 |
| Corium, LLC | 7 | $107 |
| Vanda Pharmaceuticals Inc. | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 6 | $90 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| Merck | 2 | $33 |
| Sage Therapeutics, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,288 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 26 | $40,282 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 108 | $22,634 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $21,060 |
| CaplytaLumateperone Tosylate | 13 | $20,788 |
| QuviviqDaridorexant Hcl | 13 | $6,319 |
| LinzessLinaclotide | 11 | $6,039 |
| Jentadueto XrLinagliptin/Metformin Hcl | 11 | $5,926 |
| BelbucaBuprenorphine Hcl | 12 | $4,543 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,533 |
| Buprenorphine Hcl | 79 | $3,065 |
| Clozapine | 20 | $1,831 |
| Quetiapine Fumarate | 145 | $1,687 |
| Bupropion XlBupropion Hcl | 36 | $1,686 |
| Tizanidine Hcl | 22 | $1,437 |
| Trazodone Hcl | 82 | $1,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $1,183 | $46,32137 claims |
| Indivior Inc.Suboxone | $610 | $21,06029 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $498 | $20,78813 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $90 | $6,31913 claims |
| Boehringer IngelheimJentadueto Xr | $16 | $5,92611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $246 | $4,53312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lake Charles
- Sattaria DilksLake Charles$57K
- Michelle DyerLake Charles$33K
- Erica HessiferLake Charles$13K
- Candyce BrownLake Charles$13K
- Bethanne CarsonLake Charles$12K
- Morgan UnserLake Charles$9K
- Eric RachalLake Charles$9K
- Lori KayLake Charles$9K
- Julie DyrekLake Charles$8K
- Halie OryLake Charles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.